B7-33 is an investigational, preclinical peptide with no established human dose. It has been studied in animal models, not in approved human use. Any numbers circulating online are not medically established. This page is education, not a protocol, and describes no usable regimen.
Overview
B7-33 is a single-chain analog of the hormone relaxin, engineered as a "biased agonist" of the RXFP1 receptor — it aims to trigger anti-fibrotic signaling while sparing some of relaxin's other effects. Its pharmacology is characterized mainly in laboratory and animal studies.
What is known about dosing
There is no common, validated human dosing pattern to report:
- B7-33 has been studied in preclinical (animal) research, where amounts are specific to the experiment and species.
- Those animal amounts do not translate into a human dose.
- There is no approved label, no established schedule, and no verified safe amount for human use.
Because research focuses on how a given exposure engages the receptor in model systems — not on a fixed human number — no community "dose" is anchored to validated human data.
Why no dose can be given
Quoting a number would imply a validated, safe human amount that simply does not exist yet. The compound sits at the animal-research stage. The honest educational answer is that no established dose exists and none should be inferred from preclinical data.
Why oversight matters
B7-33 acts on a receptor system with wide-ranging effects, and its human safety is uncharacterized. Any legitimate investigation would occur only within a controlled research setting with appropriate monitoring — not through self-administration.
For a broader overview, see the main B7-33 reference page and the safety-focused guide.